GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Cash Conversion Cycle

Strata Skin Sciences (Strata Skin Sciences) Cash Conversion Cycle : 75.49 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Strata Skin Sciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 48.53.
Strata Skin Sciences's Days Inventory for the three months ended in Dec. 2023 was 103.24.
Strata Skin Sciences's Days Payable for the three months ended in Dec. 2023 was 76.28.
Therefore, Strata Skin Sciences's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 75.49.


Strata Skin Sciences Cash Conversion Cycle Historical Data

The historical data trend for Strata Skin Sciences's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Cash Conversion Cycle Chart

Strata Skin Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.06 95.17 63.09 44.16 36.50

Strata Skin Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.67 83.23 99.94 106.06 75.49

Competitive Comparison of Strata Skin Sciences's Cash Conversion Cycle

For the Medical Devices subindustry, Strata Skin Sciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Cash Conversion Cycle falls into.



Strata Skin Sciences Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Strata Skin Sciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=48.75+70.66-82.91
=36.50

Strata Skin Sciences's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=48.53+103.24-76.28
=75.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strata Skin Sciences  (NAS:SSKN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Strata Skin Sciences Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Strata Skin Sciences (Strata Skin Sciences) Business Description

Traded in Other Exchanges
Address
5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
Executives
Shmuel Gov officer: SVP & General Manager Carlsbad 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein director 5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc. 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp 10 percent owner 590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz officer: Chief Financial Officer 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia director, officer: Chief Executive Officer 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang director 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727